Financial Performance - The company's operating revenue for Q1 2021 was ¥159,883,887.29, representing a 200.90% increase compared to ¥53,135,142.89 in the same period last year[8]. - Net profit attributable to shareholders was ¥13,412,026.83, a significant turnaround from a loss of ¥20,682,028.95 in the previous year, marking a 164.85% increase[8]. - The net profit after deducting non-recurring gains and losses was ¥12,228,961.09, compared to a loss of ¥21,605,883.00 last year, reflecting a 156.60% improvement[8]. - Basic earnings per share increased to ¥0.05 from a loss of ¥0.08, showing a 162.50% growth[8]. - The weighted average return on equity improved to 0.76% from -1.22% year-on-year, indicating a positive trend in profitability[8]. - Operating revenue increased by 200.90% year-on-year, reaching 160 million RMB, primarily due to the recovery of project acceptance progress after the pandemic[19]. - The net profit turned positive, amounting to 13.29 million RMB, compared to a loss in the previous year[21]. - The pharmaceutical and biological intelligent manufacturing segment achieved revenue of 124 million RMB, a year-on-year increase of 231.64%[21]. - The rehabilitation medical equipment segment reported revenue of 36.17 million RMB, up 128.47% year-on-year[23]. - The company expects to achieve a net profit of RMB 45 million to RMB 58.5 million for the first half of 2021, compared to a loss of RMB 6.248 million in the same period last year, indicating a turnaround[39]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,513,682,150.62, a slight decrease of 0.41% from ¥2,523,998,565.50 at the end of the previous year[8]. - The net assets attributable to shareholders increased by 0.54% to ¥1,773,933,440.08 from ¥1,764,492,691.06[8]. - The company's total assets decreased from ¥1,996,680,384.01 to ¥1,981,420,009.83, indicating a slight contraction in asset base[58]. - Total liabilities decreased from ¥466,070,828.12 to ¥447,021,028.17, showing a reduction in financial obligations[58]. - Total liabilities decreased from CNY 738,168,339.13 to CNY 718,537,826.57, a decline of approximately 2.6%[51]. Cash Flow - The company reported a net cash flow from operating activities of -¥70,571,036.50, which is a 2.99% decline compared to -¥68,523,709.46 in the previous year[8]. - Cash inflow from operating activities amounted to CNY 184,753,234.67, up from CNY 125,682,261.65 in the previous period, representing an increase of approximately 47%[67]. - Net cash flow from operating activities was negative at CNY -70,571,036.50, slightly worse than the previous period's CNY -68,523,709.46[67]. - Cash outflow from investing activities totaled CNY 171,929,651.59, significantly higher than CNY 45,897,911.04 in the previous period[67]. - Net cash flow from investing activities was CNY -75,029,343.52, compared to a positive CNY 3,909,278.12 in the previous period[67]. - Cash inflow from financing activities was CNY 71,957,901.82, an increase from CNY 53,941,827.93 in the previous period[68]. - Net cash flow from financing activities was CNY 16,585,912.18, down from CNY 20,959,433.86 in the previous period[68]. - The ending balance of cash and cash equivalents was CNY 90,084,031.13, compared to CNY 60,070,863.76 at the end of the previous period[68]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,408[12]. - A cash dividend of 0.16 RMB per share is proposed, totaling approximately 4.35 million RMB, subject to shareholder approval[31]. - The company plans to repurchase shares with a budget between RMB 20 million and RMB 40 million, with a maximum price of RMB 11.00 per share, and has already repurchased 530,900 shares, accounting for 0.20% of total shares[33]. Business Development - The company plans to enhance its core competitiveness by expanding into new markets and strengthening R&D capabilities[28]. - New signed and awarded contracts amount to RMB 203 million, representing a 50.01% increase compared to the same period last year[40]. - The company is actively expanding its business in the pharmaceutical and biomedical intelligent manufacturing sectors, focusing on areas such as chemical synthesis and traditional Chinese medicine[40]. - The company has successfully completed the acquisition of 100% equity in Guangzhou Longzhijie, with a total investment of RMB 11,934.72 million, achieving 100% of the planned investment[37]. - The company has made significant progress in the rehabilitation medical equipment sector, with demand recovering as the pandemic situation improves[40]. Other Information - The company received government subsidies amounting to ¥1,471,391.38 during the reporting period[9]. - The company has not encountered any overdue commitments from major stakeholders during the reporting period[35]. - The company has not reported any major changes in the feasibility of its projects during the reporting period[38]. - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[43]. - There were no violations regarding external guarantees during the reporting period[42]. - The company has not undergone an audit for the first quarter report[73].

Financial Performance - The company's operating revenue for 2020 was ¥764,426,897.86, representing a 10.92% increase compared to ¥689,199,686.20 in 2019[16] - The net profit attributable to shareholders for 2020 was ¥60,386,907.20, a decrease of 25.81% from ¥81,391,942.86 in 2019[16] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥51,479,370.81, down 33.77% from ¥77,724,698.14 in 2019[16] - The net cash flow from operating activities increased by 8.52% to ¥125,332,640.48 in 2020, compared to ¥115,487,475.35 in 2019[16] - The total assets at the end of 2020 were ¥2,523,998,565.50, reflecting a 7.55% increase from ¥2,346,880,670.27 at the end of 2019[16] - The net assets attributable to shareholders at the end of 2020 were ¥1,764,492,691.06, up 3.48% from ¥1,705,079,473.82 at the end of 2019[16] - The basic earnings per share for 2020 were ¥0.22, a decrease of 26.67% from ¥0.30 in 2019[16] - The diluted earnings per share for 2020 were also ¥0.22, down 26.67% from ¥0.30 in 2019[16] - The weighted average return on equity for 2020 was 2.97%, a decline of 1.92% from 4.89% in 2019[16] Dividend Distribution - The company plans to distribute a cash dividend of ¥0.16 per 10 shares to all shareholders, based on a total of 272,008,896 shares[6] - The cash dividend distribution represents 7.21% of the net profit attributable to shareholders for the year 2020[150] Revenue Growth and Segments - The company's total revenue for Q4 reached 305,399,263.41, showing a significant increase compared to Q1's 53,135,142.89[19] - The net profit attributable to shareholders for Q4 was 40,306,877.12, a substantial improvement from a net loss of -20,682,028.95 in Q1[19] - The net cash flow from operating activities in Q4 was 101,363,179.08, up from -68,523,709.46 in Q1, indicating a strong recovery in cash generation[19] - The company’s pharmaceutical intelligent manufacturing segment signed new orders worth 717 million yuan, a year-on-year increase of 20.93%[81] - The revenue from the pharmaceutical intelligent manufacturing business reached 598 million yuan, a year-on-year increase of 14.65%[81] - The rehabilitation medical equipment segment achieved revenue of 167 million yuan, a decrease of 0.68% year-on-year, with a net profit of 31.41 million yuan, down 39.11% year-on-year[87] Market Expansion and Strategy - The company has established a dual-driven development strategy focusing on the health sector, integrating pharmaceutical bio-intelligent manufacturing and rehabilitation medical equipment[26] - The company aims to expand its product offerings and enhance its intelligent manufacturing solutions to meet the evolving needs of the pharmaceutical sector[36] - The company plans to continue its focus on expanding its market presence and developing new technologies in the healthcare sector[36] - The company is actively expanding its market presence through exhibitions, seminars, and online media to promote its intelligent manufacturing systems to major pharmaceutical and biological enterprises[63] - The company aims to accelerate market penetration by enhancing sales team coverage in county and township medical institutions, promoting the construction of rehabilitation disciplines[52] Research and Development - The company's R&D expenditure for 2020 was ¥49,130,788.61, accounting for 6.43% of total revenue, with a year-on-year increase of 10.76%[105] - The company is committed to continuous R&D investment, enhancing product safety and user experience through upgrades and new features[89] - The company plans to launch five new information technology products in 2021, enhancing its product intelligence level[85] - The company will continue to increase R&D investment in the field of pharmaceutical biotechnology and smart manufacturing, focusing on product informatization and intelligentization[133] Product Development and Innovation - The company has developed a comprehensive solution for industrial hemp purification and processing, and has established a subsidiary in the United States for business expansion in this area[37] - The company has formed a complete system solution in the pharmaceutical manufacturing process, including intelligent logistics, mixing, and packaging systems, enhancing its overall solution capabilities[38] - The company has a product range covering rehabilitation assessment, training, and physical therapy, establishing a comprehensive product system in the rehabilitation medical device sector[41] - The company is focusing on the development of smart wearable rehabilitation devices, leveraging partnerships with renowned rehabilitation institutions to cater to the C-end user market[56] Compliance and Governance - The company has established a risk control system for R&D projects to mitigate potential risks associated with new product development[137] - The company has ensured that no illegal transfer of funds or profits occurs through related party transactions, protecting the interests of non-related shareholders[152] - The company has established measures to ensure compliance with legal and regulatory requirements regarding share transfers[153] - The company has implemented an employee incentive plan approved by the board and shareholders, in accordance with relevant laws and regulations[164] Social Responsibility and Community Engagement - The company has contributed to social responsibility by donating medical equipment during the COVID-19 pandemic to various hospitals[193] - The company has actively engaged in community relations and social welfare activities, including campus recruitment events for students[192] - The company emphasizes environmental protection and sustainable development, actively promoting energy conservation and waste reduction initiatives[191] Share Structure and Ownership - The total number of shares is 272,008,896, with 100% of shares accounted for[200] - Limited sale condition shares decreased from 48,498,359 (17.83%) to 16,924,112 (6.22%) after a reduction of 31,574,247 shares[200] - Unlimited sale condition shares increased from 223,510,537 (82.17%) to 255,084,784 (93.78%) after an addition of 31,574,247 shares[200] - The company unlocked 9,345,107 shares for public trading on April 17, 2020, following the expiration of the lock-up period for a portion of non-publicly issued shares[200]

Financial Performance - Operating revenue for the reporting period was ¥227,875,415.86, representing a year-on-year increase of 67.57%[7] - Net profit attributable to shareholders was ¥26,328,058.11, a significant increase of 167.18% compared to the same period last year[7] - Basic earnings per share for the reporting period was ¥0.10, up 150.00% compared to the same period last year[7] - The company reported a net profit of ¥25,307,656.48 after deducting non-recurring gains and losses, which is an increase of 167.73% year-on-year[7] - The total operating revenue for Q3 2020 was CNY 227,875,415.86, compared to CNY 135,986,044.75 in the same period last year, indicating a significant increase[35] - The net profit for Q3 2020 reached CNY 27,697,884.12, compared to CNY 10,816,415.35 in Q3 2019, reflecting a growth of approximately 156%[37] - The company's operating revenue for the current period reached ¥98,570,973.37, compared to ¥64,778,049.85 in the previous period, indicating a significant increase[40] - The net profit for the current period was ¥5,097,573.19, up from ¥2,137,616.64 in the previous period, reflecting a growth of approximately 138%[41] - The total profit for the current period was ¥5,360,763.98, compared to ¥2,281,879.17 in the previous period, reflecting an increase of approximately 135%[41] Cash Flow - The net cash flow from operating activities was ¥59,977,550.07, showing a remarkable increase of 412.87% year-on-year[7] - Cash flow from operating activities increased by 21,587.43% compared to the same period last year, mainly due to a decrease in cash paid for goods and services[18] - The net cash flow from operating activities is CNY 23,969,461.40, a substantial increase compared to CNY 110,522.37 in the previous period[53] - The net cash flow from financing activities decreased to 51,110,122.62 CNY from 78,321,643.97 CNY in the previous period, indicating a decline in financing efficiency[54] - The company’s cash inflow from financing activities was impacted by a significant increase in debt repayment, totaling 130,759,243.88 CNY, compared to 63,982,515.70 CNY in the previous period[54] - The company reported a credit impairment loss of ¥-3,386,848.18, compared to ¥-345,096.62 in the previous period, indicating a deterioration in credit quality[41] Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,482,716,240.66, an increase of 5.79% compared to the end of the previous year[7] - Total liabilities as of September 30, 2020, were CNY 736,748,706.64, up from CNY 620,876,937.42 at the end of 2019[29] - The company reported a 100% increase in long-term borrowings compared to the beginning of the year, reflecting an increase in bank long-term loans[16] - The total assets as of September 30, 2020, amounted to CNY 2,482,716,240.66, an increase from CNY 2,346,880,670.27 at the end of 2019[28] - The total amount of short-term loans was CNY 148,899,273.81[61] - The total amount of accounts payable was CNY 123,736,770.57[61] Shareholder Information - The total number of shareholders at the end of the reporting period was 11,329[11] - The largest shareholder, Beijing Liweit Investment Co., Ltd., held 18.83% of the shares[11] Research and Development - The research and development expenses for Q3 2020 were CNY 13,053,534.18, compared to CNY 11,231,085.04 in the same quarter last year, reflecting a growth of approximately 16.2%[36] - Research and development expenses rose to ¥5,026,802.68, compared to ¥2,554,639.14 in the previous period, marking a 97% increase[40] - Research and development expenses increased to CNY 10,699,572.77, up from CNY 5,934,238.10, marking an increase of 80.5%[48] Other Financial Metrics - The weighted average return on net assets was 1.53%, an increase from 0.94% in the previous year[7] - Financial expenses increased by 85.87% compared to the same period last year, primarily due to higher interest expenses on bank loans[17] - Investment income decreased by 233.84% compared to the same period last year, mainly due to reduced returns from bank wealth management and equity investments[17] - The total operating costs for the current period were ¥439,753,737.46, up from ¥411,947,704.18 in the previous period[43] - The total comprehensive income attributable to the parent company was ¥26,270,277.85, compared to ¥9,853,906.08 in the previous period, showing a substantial growth[41] - The total comprehensive income attributable to the parent company is CNY 20,096,508.49, down from CNY 54,127,760.09, reflecting a decrease of 62.9%[48]

Financial Performance - The company's operating revenue for the first half of 2020 was ¥231,152,218.59, a decrease of 30.68% compared to ¥333,433,364.54 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was -¥6,248,028.03, representing a decline of 114.11% from ¥44,273,854.01 in the previous year[18]. - The net cash flow from operating activities was -¥36,008,088.67, a significant decrease of 286.76% compared to ¥19,280,428.99 in the same period last year[18]. - The basic earnings per share were -¥0.02, down 112.50% from ¥0.16 in the previous year[18]. - Total revenue for the reporting period was 231.15 million yuan, down 30.68% year-on-year, primarily due to the pandemic's impact[75]. - The net profit for the first half of 2020 was a loss of CNY 5.93 million, compared to a net profit of CNY 44.98 million in the first half of 2019[173]. - The total comprehensive income for the first half of 2020 was -3,096,477.68 CNY, compared to 15,479,739.40 CNY in the same period of 2019, marking a decline of around 120%[178]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,420,174,032.07, an increase of 3.12% from ¥2,346,880,670.27 at the end of the previous year[18]. - The company's equity attributable to shareholders was CNY 1,698,905,704.46, slightly down from CNY 1,705,079,473.82, indicating a decrease of about 0.8%[166]. - Total liabilities reached CNY 700,778,378.73, up from CNY 620,876,937.42, reflecting an increase of around 12.9%[166]. - The company's total liabilities were approximately 8,120.39 million yuan, indicating a manageable debt level relative to its assets[191]. Business Strategy and Development - The company has expanded its business into the rehabilitation medical equipment sector, with nearly 40 listed products covering various rehabilitation fields[34]. - The company has established a dual-directional business layout, expanding horizontally into chemical synthesis and traditional Chinese medicine extraction, which are expected to drive future growth[30]. - The company aims to enhance its core competitiveness in rehabilitation medical devices by increasing R&D investment and launching new products to meet global market demands[34]. - The company is focusing on the development of sub-specialty rehabilitation to meet the increasing market demand driven by aging populations and healthcare needs[39]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[192]. Research and Development - R&D investment reached 24.01 million yuan, accounting for 10.39% of total revenue, an increase of 24.24% compared to the same period last year[65]. - The company aims to leverage its R&D resources and partnerships to become a leading player in the wearable medical device sector[43]. - The company plans to enhance its research and development capabilities to address market competition and improve product offerings, focusing on expanding its product chain and enhancing customer loyalty[102]. Risk Management - The company has faced significant risks and has outlined measures to address these risks in the report[4]. - The company emphasizes the importance of investors maintaining risk awareness regarding future operational plans[4]. - The company faces risks related to technology development and new product launches, including potential cost overruns and the inability to commercialize new technologies[103]. Corporate Governance - The company has undergone a change in its board of directors and senior management as of June 10, 2020[17]. - The company did not distribute cash dividends or issue new shares during the reporting period, maintaining its capital structure[110]. - The company has not undergone any major litigation or arbitration matters during the reporting period[115]. Market Trends - The rehabilitation medical device market in China reached a scale of 450 billion RMB in 2018, projected to grow to 1,033 billion RMB by 2022[53]. - The C-end user market in China's healthcare sector is expected to become a blue ocean market, with the company developing smart wearable rehabilitation devices tailored for domestic needs[43]. - The rehabilitation medical device industry in China is in a growth phase, with significant room for development compared to developed countries[57]. Financial Management - The company has a comprehensive supplier assessment system to ensure timely procurement of raw materials and components for rehabilitation medical devices[46]. - The company focuses on a stock production model for standardized products, ensuring timely delivery upon customer orders[48]. - The company has made provisions for general risk reserves, emphasizing its commitment to financial prudence[191]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 12,035[144]. - The largest shareholder, Beijing Liweit Investment Co., Ltd., holds 25.81% of the shares, totaling 70,209,771 shares[145]. - The company has not undergone any changes in controlling shareholders during the reporting period[147].

北京诚益通控制工程科技股份有限公司 2020 年第一季度报告全文 北京诚益通控制工程科技股份有限公司 2020 年第一季度报告 2020-029 2020 年 04 月 1 北京诚益通控制工程科技股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人梁学贤、主管会计工作负责人乌吉斯古楞及会计机构负责人(会 计主管人员)冯双声明：保证季度报告中财务报表的真实、准确、完整。 2 北京诚益通控制工程科技股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 53,135,142.89 | 147,980,491.02 | -64.09% | | 归属于上市公司股东的净 ...

Financial Performance - The company's operating revenue for 2019 was CNY 689,199,686.20, a slight increase of 0.01% compared to CNY 689,136,877.33 in 2018[15]. - The net profit attributable to shareholders decreased by 20.44% to CNY 81,391,942.86 from CNY 102,304,940.61 in the previous year[15]. - The net profit after deducting non-recurring gains and losses was CNY 77,724,698.14, down 21.43% from CNY 98,929,988.08 in 2018[15]. - The net cash flow from operating activities significantly increased by 704.53% to CNY 115,487,475.35, compared to CNY 14,354,706.28 in 2018[15]. - The total assets at the end of 2019 reached CNY 2,346,880,670.27, reflecting a growth of 10.52% from CNY 2,123,484,105.58 in 2018[15]. - The net assets attributable to shareholders increased by 4.95% to CNY 1,705,079,473.82 from CNY 1,624,616,636.52 in the previous year[15]. - Basic earnings per share decreased by 21.05% to CNY 0.30 from CNY 0.38 in 2018[15]. - The weighted average return on equity was 4.89%, down from 6.46% in the previous year[15]. - In 2019, the company achieved total revenue of CNY 689.20 million, a year-on-year increase of 0.01%[62]. - The net profit attributable to shareholders was CNY 81.39 million, a decrease of 20.44% compared to the previous year[62]. - The total assets reached CNY 2.347 billion, reflecting a year-on-year growth of 10.52%[62]. - The pharmaceutical intelligent manufacturing segment generated revenue of CNY 521.34 million, down 0.54% year-on-year, with a gross margin of 33.15%[63]. - The rehabilitation medical equipment segment reported revenue of CNY 167.86 million, an increase of 1.76% year-on-year[67]. Business Expansion and Strategy - The company has expanded its business into the rehabilitation medical equipment sector, with nearly 40 products launched in various rehabilitation fields by the end of the reporting period[31]. - The company has established a chemical synthesis division and acquired Zhejiang Jin'an to enhance its automation control capabilities in the traditional Chinese medicine extraction field[28]. - The company has developed an intelligent manufacturing execution system (iMES) and successfully applied it in several national-level intelligent manufacturing projects[30]. - The company aims to enhance its market presence in the rehabilitation medical equipment sector, focusing on technological innovation and product leadership to maximize sales outcomes[32]. - The company has adopted an EPC (Engineering Procurement Construction) model to optimize project costs and timelines, enhancing resource allocation efficiency[26]. - The company has extended its service offerings to the formulation production sector, creating a comprehensive solution that includes intelligent logistics and packaging systems[29]. - The company has identified the biopharmaceutical sector as a key growth area, aiming to cultivate it as a new business development direction[28]. - The company plans to utilize IoT, cloud storage, and big data technologies to upgrade approximately 30,000 rehabilitation medical devices currently in use, enhancing their functionality and data management capabilities[40]. - The company is focusing on expanding its market share in the maternal and child rehabilitation sector following its acquisition of Guangzhou Shiru, establishing a four-tier integrated rehabilitation system[36]. - The company plans to focus on expanding its business in chemical synthesis, plant extraction, and formulation areas in 2020[134]. Research and Development - Research and development expenses reached ¥44,359,681.26, an increase of 28.45% compared to the previous year, reflecting a significant rise in R&D investment[87]. - The company's R&D investment accounted for 6.44% of total revenue, up from 5.41% in the previous year[89]. - The company will continue to increase R&D investment, particularly in information technology, to enhance product intelligence and meet customer needs through new product development[118]. Market Trends and Opportunities - The rehabilitation medical device market in China reached a scale of 45 billion RMB in 2018, projected to grow to 103.3 billion RMB by 2022[51]. - The C-end user market in China's healthcare sector is expected to become a blue ocean market, with the company focusing on developing smart wearable rehabilitation devices tailored for domestic needs[41]. - The company highlights the potential for growth in the rehabilitation medical device sector, with only 30% of disabled individuals receiving basic rehabilitation services[115]. - The company notes that the number of rehabilitation institutions in China is significantly lower than in the U.S., indicating substantial growth potential in the rehabilitation medical field[115]. Corporate Governance and Compliance - The company has fulfilled its commitments regarding related party transactions during the reporting period[135]. - The company has committed to not engaging in any business that competes with Chengyitong, ensuring no conflicts of interest[141]. - The company has not experienced significant changes in project feasibility, and the pharmaceutical and biological engineering automation control system project has been put into production despite a decrease in orders due to macroeconomic factors[106]. - The company has not undergone any significant litigation or arbitration matters during the reporting period[152]. - The company has not issued any external guarantees during the reporting period, with both approved and actual amounts being zero[168]. Shareholder Information - The company has a total of 272,008,896 shares as of the report period, with no cash dividends or capital reserve transfers planned for 2019[128]. - The company reported a net profit available for distribution to ordinary shareholders, but no cash dividend distribution plan was proposed for 2019[133]. - The company’s stock unlock events included 29,081,504 shares on April 12, 2019, and 7,175,617 shares on April 22, 2019[189]. - The total number of ordinary shareholders at the end of the reporting period was 12,588, a slight increase from 12,538 at the end of the previous month[194]. - The largest individual shareholder, Liang Xuexian, owns 6.78% of the shares, amounting to 18,455,040 shares, with 13,841,280 shares under lock-up conditions[194]. Future Outlook - The company anticipates that healthcare expenditure will reach 6.5%-7% of GDP by 2020, driving growth in the pharmaceutical manufacturing industry[113]. - In 2020, the company plans to deepen its focus on biopharmaceutical manufacturing and expand its market share in rehabilitation medical devices, aiming to establish a leading position in the industry[117]. - The company will strengthen compliance management to improve efficiency and reduce costs, enhancing risk control across departments and subsidiaries[119].

北京诚益通控制工程科技股份有限公司 2019 年第三季度报告全文 所有董事均已出席了审议本次季报的董事会会议。 公司负责人梁学贤、主管会计工作负责人乌吉斯古楞及会计机构负责人(会 计主管人员)冯双声明：保证季度报告中财务报表的真实、准确、完整。 2019 年 10 月 1 北京诚益通控制工程科技股份有限公司 北京诚益通控制工程科技股份有限公司 2019 年第三季度报告全文 2019 年第三季度报告 第一节 重要提示 2019-080 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 2 北京诚益通控制工程科技股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 2,329,633,682.32 | 2,123,484,105.58 | | 9.71% | ...

Financial Performance - Total operating revenue for the reporting period was ¥333,433,364.54, an increase of 2.22% compared to ¥326,179,929.46 in the same period last year[16]. - Net profit attributable to shareholders was ¥44,273,854.01, a decrease of 8.23% from ¥48,241,793.71 in the previous year[16]. - Net profit after deducting non-recurring gains and losses was ¥42,625,532.06, down 10.44% from ¥47,595,655.32 year-on-year[16]. - Basic earnings per share decreased to ¥0.16, down 11.11% from ¥0.18 in the same period last year[16]. - Diluted earnings per share also fell to ¥0.16, a decrease of 11.11% compared to ¥0.18 in the previous year[16]. - The weighted average return on net assets was 2.69%, down from 3.10% in the previous year[16]. - The total profit amounted to CNY 48.63 million, representing a year-on-year decrease of 12.89%[24]. - Net profit attributable to shareholders was CNY 44.27 million, down 8.23% year-on-year[24]. - The biopharmaceutical intelligent manufacturing business generated revenue of CNY 260.60 million, up 2.48% year-on-year, but net profit fell by 22.28% to CNY 25.20 million[42]. - The rehabilitation medical device segment, "Longzhijie," reported revenue of CNY 72.86 million, a growth of 7.70%, with net profit increasing by 25.54% to CNY 20.22 million[47]. Cash Flow and Assets - Net cash flow from operating activities reached ¥19,280,428.99, a significant increase of 387.08% compared to a negative cash flow of ¥6,715,984.53 in the previous year[16]. - Total assets at the end of the reporting period were ¥2,263,880,642.79, reflecting a growth of 6.61% from ¥2,123,484,105.58 at the end of the previous year[16]. - The company’s total assets reached CNY 2.26 billion, reflecting a year-on-year growth of 6.61%[41]. - The company’s cash and cash equivalents decreased from 233,812,491.75 RMB at the end of 2018 to 162,361,173.70 RMB by June 30, 2019, a decline of approximately 30.5%[132]. - The total liabilities amounted to CNY 577,092,915.98, up from CNY 483,778,994.90, indicating a rise of approximately 19.36%[135]. Investments and Acquisitions - The company established a joint venture, Beijing Chengyitong Wanjielang Biotechnology Co., Ltd., holding 55% of the shares, to promote chlorine dioxide disinfection technology in the medical market[26]. - The company acquired 65% of Guangzhou Zhanghe Intelligent Technology Co., Ltd., enhancing its position in the rehabilitation medical device sector[30]. - The company has expanded its market presence by acquiring a 55% stake in Jin'an Pharmaceutical Machinery and establishing a subsidiary in the U.S. for industrial hemp CBD extraction[43]. - The company signed a strategic cooperation agreement with Germany's ERGO-FIT GmbH & Co.KG to enhance its rehabilitation medical product system[31]. Research and Development - The company emphasizes continuous R&D investment to provide high-quality products and services in the health sector[25]. - The company’s R&D investment increased by 35.95% to RMB 19,327,613.67, up from RMB 14,216,882.30, reflecting a commitment to enhancing product development[52]. - The company has developed a comprehensive research and design system in the biopharmaceutical intelligent manufacturing sector, focusing on high-tech value-added research outcomes[35]. - The company is focusing on integrating resources and extending the industrial chain in the biopharmaceutical sector, including automation in raw material and formulation production[43]. Market Strategy and Expansion - The company plans to expand into the North American market, establishing a wholly-owned subsidiary in the U.S. to tap into new profit growth points[28]. - The company plans to expand its marketing efforts into county-level medical institutions and community healthcare, responding to national policies[49]. - The company aims to deepen its market penetration and achieve performance growth through a "one body, two wings, dual-wheel drive" development strategy[39]. - The company is focused on expanding its technology and product offerings in the biotechnology and medical device sectors[109]. Financial Management and Governance - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company has committed to fulfilling performance promises related to net profits for the years 2016 to 2018, ensuring compliance with its obligations[84]. - The half-year financial report has not been audited, indicating a lack of external validation for the reported figures[86]. - The financial report was approved by the board of directors on August 27, 2019, reflecting timely governance practices[171]. Risks and Challenges - The company faces risks in technology development and new product innovation due to high R&D costs and long cycles[77]. - Increased market competition is anticipated as downstream clients demand more comprehensive solutions, prompting the company to enhance its R&D capabilities[78]. - The company has established a risk control system for R&D projects to mitigate potential development failures and cost overruns[77]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 12,494[118]. - Beijing Liweit Investment Co., Ltd. holds 25.81% of shares, totaling 70,209,771 shares, with 47,813,976 shares pledged[118]. - The largest individual shareholder, Liang Xuexian, holds 6.78% of shares, totaling 18,455,040 shares[118]. - The first employee stock ownership plan acquired a total of 3,584,426 shares, representing approximately 1.98% of the company's total equity, with a transaction amount of RMB 80,137,012.08 and an average price of RMB 22.357 per share[90].

北京诚益通控制工程科技股份有限公司 2019 年第一季度报告全文 北京诚益通控制工程科技股份有限公司 2019 年第一季度报告 2019-045 2019 年 04 月 1 北京诚益通控制工程科技股份有限公司 2019 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人梁学贤、主管会计工作负责人乌吉斯古楞及会计机构负责人(会 计主管人员)冯双声明：保证季度报告中财务报表的真实、准确、完整。 2 北京诚益通控制工程科技股份有限公司 2019 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 147,980,491.02 | 109,038,688.88 | 35.71% | | 归属于上市公司股东的净 ...

Financial Performance - The company's operating revenue for 2018 was approximately ¥689.14 million, representing a 24.14% increase compared to ¥555.13 million in 2017[19]. - The net profit attributable to shareholders for 2018 was approximately ¥102.30 million, an increase of 14.18% from ¥89.60 million in 2017[19]. - The total profit reached 118.98 million yuan, reflecting a year-on-year growth of 15.52%[27]. - The basic earnings per share for 2018 were ¥0.38, an increase of 8.57% compared to ¥0.35 in 2017[19]. - The company achieved total operating revenue of 68,913.69 million yuan, a year-on-year increase of 24.14%[52]. - The net profit attributable to shareholders was 10,230.49 million yuan, up 14.18% year-on-year[52]. - The gross profit margin for rehabilitation medical equipment was 70.97%, an increase of 5.49% compared to the previous year[62]. Cash Flow and Assets - The net cash flow from operating activities improved significantly to approximately ¥14.35 million, a 166.28% increase from a negative cash flow of ¥21.66 million in 2017[19]. - The total assets at the end of 2018 were approximately ¥2.12 billion, an increase of 11.84% from ¥1.90 billion at the end of 2017[19]. - The net assets attributable to shareholders at the end of 2018 were approximately ¥1.62 billion, reflecting a 6.01% increase from ¥1.53 billion at the end of 2017[19]. - The company reported an investment income of CNY 3.57 million, contributing 3.00% to total profit[75]. - The company has temporarily used CNY 50 million of raised funds to supplement working capital, with a remaining balance of CNY 16.41 million as of December 31, 2018[82]. Research and Development - The company invested 37.3 million yuan in R&D in 2018, accounting for 5.41% of its total revenue, and employed 301 R&D personnel[41]. - The company focused on the development of the iMES platform for digital workshop integration during the reporting period[31]. - The company is focused on technological innovation and product development as core drivers for growth in the competitive medical and rehabilitation equipment sectors[40]. - The number of R&D personnel increased to 301, accounting for 22.56% of the workforce, reflecting the company's commitment to innovation[72]. Market Expansion and Acquisitions - The company launched a new "pulse air mixing equipment" to expand its business scope in the veterinary medicine and health food sectors[30]. - The company acquired a controlling stake in Zhejiang Jin'an Pharmaceutical Machinery Co., further expanding its business into the traditional Chinese medicine market[27]. - The company completed four acquisitions from 2017 to 2018, extending its industrial chain and enhancing market presence[42]. - The company plans to deepen its focus on the pharmaceutical and biological intelligent manufacturing sector and expand its market share in rehabilitation medical devices, aiming to create new growth engines[96]. Shareholder and Dividend Policy - The company plans not to distribute cash dividends or issue bonus shares for the year[6]. - The company reported no cash dividends or stock bonuses for the year 2018, with retained earnings carried forward to the next year[108]. - The company did not propose a cash dividend distribution plan for the reporting period despite having positive distributable profits, citing the need for liquidity for future investments in biomedicine and intelligent manufacturing projects[113]. - The stock increase and cash dividends reflect the company's commitment to returning value to shareholders while balancing growth investments[112]. Risks and Challenges - The company has faced risks as outlined in the future development outlook section of the report[5]. - The company faces risks in technology R&D and new product development, including potential deviations in R&D direction and high costs, which could adversely affect financial status if not managed properly[100]. - The company anticipates intensified market competition as downstream clients demand more comprehensive solutions, prompting a need for enhanced brand and product development strategies[102]. Corporate Governance and Management - The company has established measures to ensure that any business opportunities that may compete with its operations are prioritized for acquisition by the company[120]. - The company has a structured approach to managing potential conflicts of interest among its shareholders and controlling parties[120]. - The company has maintained a consistent leadership team, with key management personnel serving for several years, ensuring continuity in operations[188]. - The total remuneration paid to directors, supervisors, and senior management in 2018 amounted to CNY 3.0395 million[190].